Compare VTOL & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | NVAX |
|---|---|---|
| Founded | 1948 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 1996 |
| Metric | VTOL | NVAX |
|---|---|---|
| Price | $45.59 | $7.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $58.00 | $11.33 |
| AVG Volume (30 Days) | 190.7K | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | 34.58 | ★ 309.76 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,490,512,000.00 | $1,123,479,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $102.64 | ★ N/A |
| Revenue Growth | 5.30 | ★ 64.69 |
| 52 Week Low | $32.76 | $6.20 |
| 52 Week High | $50.38 | $11.85 |
| Indicator | VTOL | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 30.13 |
| Support Level | $42.83 | $6.38 |
| Resistance Level | $46.36 | $10.10 |
| Average True Range (ATR) | 1.10 | 0.37 |
| MACD | 0.29 | -0.14 |
| Stochastic Oscillator | 80.95 | 2.03 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers are in the UK, Norway, the USA, Nigeria, and Others. The offshore energy customers use services to transport personnel to, from and between offshore energy installations. The majority of revenue is generated from Offshore Energy Services.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.